Health
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Elecsys® pTau217 is the first blood test for Alzheimer’s disease pathology with a single‑assay design, intended to rule in and rule out amyloid pathology across primary and secondary care, offering faster diagnosis for millions of patients around the world.1,2,5While maintaining accuracy comparable to spinal fluid diagnostics against the gold standard PET-CT scans, the Elecsys® pTau217 test offers a more convenient, minimally invasive alternative via a routine blood draw.1,2,4,7,8,11Diagnosing d
About this update from Roche Holding Ltd
[{"type":"image","alt":"F. Hoffmann-La Roche Ltd","displaySize":"","headline":null,"caption":"F. Hoffmann-La Roche Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":198,"url":"https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MSaNoVyiQkMLafN4Lv5PPQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3Nw--/https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2","width":300,"height":198},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/MSaNoVyiQkMLafN4Lv5PPQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3Nw--/https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2","width":300,"height":198}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Elecsys® pTau217 is the first blood test for Alzheimer’s disease pathology with a single‑assay design, intended to rule in and rule out amyloid pathology across primary and secondary care, offering faster diagnosis for millions of patients around the world.1,2,5","length":262,"tagName":"p"}]},{"val":[{"type":"text","content":"While maintaining accuracy comparable to spinal fluid diagnostics against the gold standard PET-CT scans, the Elecsys® pTau217 test offers a more convenient, minimally invasive alternative via a routine blood draw.1,2,4,7,8,11","length":226,"tagName":"p"}]},{"val":[{"type":"text","content":"Diagnosing dementia currently takes 3.5 years on average,11 and an estimated 75% of people living with dementia remain undiagnosed.6,9,11 Elecsys® pTau217 offers a simple blood test to aid in earlier, more accessible Alzheimer's disease diagnosis for millions of patients around the world.1,2,4,5,7,8","length":304,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":792,"olType":false},{"type":"text","content":"Basel, 12 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has received CE Mark for Elecsys® pTau217, a blood test developed in collaboration with Eli Lilly and Company and designed to measure the phosphorylated Tau (pTau) 217 protein, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease.1,2,4,7,8 The same cutoffs (high and low) of the blood test can be used across primary and secondary care settings, to rule in or rule out amyloid pathology in people presenting with symptoms or complaints...